These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16370198)

  • 21. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.
    Abraham NS; El-Serag HB; Hartman C; Richardson P; Deswal A
    Aliment Pharmacol Ther; 2007 Apr; 25(8):913-24. PubMed ID: 17402995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
    Hudson M; Rahme E; Richard H; Pilote L
    Arthritis Rheum; 2007 Apr; 57(3):516-23. PubMed ID: 17394181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population.
    García Rodríguez LA; Tacconelli S; Patrignani P
    J Am Coll Cardiol; 2008 Nov; 52(20):1628-36. PubMed ID: 18992652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
    Singh H
    South Med J; 2007 Aug; 100(8):856. PubMed ID: 17713322
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [NSAIDs and coxibs raise blood pressure].
    Krankenpfl J; 2005; 43(7-10):199. PubMed ID: 16515271
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis.
    Singh G; Wu O; Langhorne P; Madhok R
    Arthritis Res Ther; 2006; 8(5):R153. PubMed ID: 16995929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
    Warner JJ; Weideman RA; Kelly KC; Brilakis ES; Banerjee S; Cunningham F; Harford WV; Kazi S; Little BB; Cryer B
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):252-60. PubMed ID: 18787084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclooxygenase 2 controversy: thoughts on the process of discovery, development, and assessment of benefit and risk of therapies for chronic immunoinflammatory diseases of uncertain autoimmune etiology.
    Furst DE; Khanna D; Paulus HE
    Arthritis Rheum; 2006 Oct; 55(5):683-6. PubMed ID: 17013849
    [No Abstract]   [Full Text] [Related]  

  • 34. A Review on the risk of myocardial infarction associated with the NSAID diclofenac.
    Krötz F; Struthmann L
    Cardiovasc Hematol Disord Drug Targets; 2010 Mar; 10(1):53-65. PubMed ID: 20092437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis.
    Schneider V; Lévesque LE; Zhang B; Hutchinson T; Brophy JM
    Am J Epidemiol; 2006 Nov; 164(9):881-9. PubMed ID: 17005625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
    Farkouh ME; Greenberg BP
    Am J Cardiol; 2009 May; 103(9):1227-37. PubMed ID: 19406264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study.
    Fosbøl EL; Gislason GH; Jacobsen S; Folke F; Hansen ML; Schramm TK; Sørensen R; Rasmussen JN; Andersen SS; Abildstrom SZ; Traerup J; Poulsen HE; Rasmussen S; Køber L; Torp-Pedersen C
    Clin Pharmacol Ther; 2009 Feb; 85(2):190-7. PubMed ID: 18987620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
    Chan FK
    Nat Clin Pract Gastroenterol Hepatol; 2006 Oct; 3(10):563-73. PubMed ID: 17008926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs.
    Warner TD; Mitchell JA
    Lancet; 2008 Jan; 371(9608):270-3. PubMed ID: 18207021
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.